Avecho Biotechnology (ASX:AVE) has moved a major step closer to completing its pivotal Phase 3 study of a TPM-enhanced cannabidiol capsule for insomnia after an independent Data Monitoring Board unanimously recommended the trial continue to its originally planned enrolment of 519 participants.
The DMB conclusion followed an unblinded interim analysis of data from 244 participants and confirmed that the study met the pre-specified criteria to proceed with recruitment of a second cohort, thereby reducing clinical development risk and preserving the trial design assumptions that guided the program.
Investors responded by boosting the company's share price by over 30 per cent.
The interim review covered three nightly treatment groups receiving either 150 milligrams CBD, 75 milligrams CBD or placebo over eight weeks and found no serious adverse events across the 244 participants assessed to date.
Avecho said tolerability is central to the product’s commercial rationale and that the safety data at interim analysis further supported continuation.
Avecho CEO Dr Paul Gavin said, “This is an important and major milestone for Avecho, and exactly the outcome we designed this trial to achieve. The independent DMB has recommended we continue at the originally planned size of 519 participants, without the need to dose additional participants.
“That recommendation carries a clear message: the treatment effect and the variability in the data are tracking closely with the assumptions this study was built around. We have always said the trial’s design — its two independent endpoints, stringent inclusion and exclusion criteria, and controls on the placebo effect — was its greatest strength in giving the product the best chance to show its effect, and the positive DMB recommendation vindicates that approach.
“Although we remain blinded and the study is not complete, so final outcomes cannot be determined until then, we are more confident than ever that our CBD capsule works as a treatment for insomnia.”
Avecho said the interim result strengthens its licensing position outside Australia and supports ongoing regulatory engagement with agencies, including the US Food and Drug Administration and European authorities. The company already granted Australian commercial rights to Sandoz in 2025 in a deal that included a US$3 million upfront payment, potential milestones, and royalties.
Avecho said it will immediately prepare to recruit the second patient cohort using its existing clinical site network and has identified additional sites to accelerate enrolment. The company expects recruitment of the remaining participants to take approximately 12 months once the extra sites are active and says it intends to fund this stage principally through regional licensing agreements.
